- Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors
-
Many diseases are believed to be driven by pathological levels of reactive oxygen species (ROS) and oxidative stress has long been recognized as a driver for inflammatory disorders. Apoptosis signal-regulating kinase 1 (ASK1) has been reported to be activ
- Lovering, Frank,Morgan, Paul,Allais, Christophe,Aulabaugh, Ann,Brodfuehrer, Joanne,Chang, Jeanne,Coe, Jotham,Ding, WeiDong,Dowty, Heather,Fleming, Margaret,Frisbie, Richard,Guzova, Julia,Hepworth, David,Jasti, Jayasankar,Kortum, Steve,Kurumbail, Ravi,Mohan, Shashi,Papaioannou, Nikolaos,Strohbach, Joseph W.,Vincent, Fabien,Lee, Katherine,Zapf, Christoph W.
-
p. 606 - 621
(2018/01/19)
-
- COMPOUNDS AND METHODS for the inhibition of HDAC
-
Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.
- -
-
Paragraph 0427-0428; 0817-0818
(2015/11/24)
-
- NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
-
The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.
- -
-
Page/Page column 74
(2010/06/11)
-
- NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
-
The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
- -
-
-
- NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
-
The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, and R4 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
- -
-
Page/Page column 25
(2008/12/09)
-
- NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
-
The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, R4, L2 and A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
- -
-
Page/Page column 36
(2008/12/07)
-
- PHARMACEUTICAL COMPOUNDS
-
The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDKl , Chk (e.g. Cbkl or Chk2),
- -
-
Page/Page column 205-206
(2010/11/28)
-
- BENZAMIDE DERIVATIVE
-
To provide compounds which have high angiogenesis inhibiting activity, and are useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, for example, cancer and cancer metastasis, methods for producing the comp
- -
-
Page/Page column 78-79
(2010/11/23)
-
- PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES
-
The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions con
- -
-
Page/Page column 146-147
(2008/06/13)
-